Abstracts tagged "comparative effectiveness"

Abstract Number: 1613 • ACR Convergence 2025
Switching From Reference Tocilizumab to Biosimilar in Giant Cell Arteritis: Effectiveness and Safety in a Multicenter Study of 38 Patients
Adrian Martin-Gutierrez¹, Fernando Lopez Gutierrez², Javier Loricera³, Juan Molina-Collada⁴, Juan Carlos Nieto⁵, Marina Sánchez-Lucas⁶, Maite silva⁷, Patricia Moya Albarado⁸, Eztizen Labrador-Sanchez⁹, Ivan Ferraz Amaro¹⁰ and Ricardo Blanco¹¹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain, ⁷Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, Galicia, Spain, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹Hospital Universitario San Pedro, Laguardia, Spain, ¹⁰Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: The cost of original biologics may limit treatment access. Biosimilars are biologics that are structurally highly similar and functionally equivalent to the approved reference…
Abstract Number: 1453 • ACR Convergence 2025
Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, William Tillett², Xiaolan Ye³, Christopher Saffore⁴, Molly Edwards⁵, Isabel Truman⁵, Sophie Barlow⁶, Jayne Stigler⁷, Bhumik Parikh⁸ and Daniel Aletaha⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³AbbVie Inc., Mettawa, IL, ⁴AbbVie Inc., waukegan, IL, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Round Lake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹Medical University Vienna, Wien, Austria
Background/Purpose: The aim of this study was to compare the effectiveness of switching from a first-line TNFi to upadacitinib (UPA), an oral JAKi, versus cycling…
Abstract Number: 1439 • ACR Convergence 2025
Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Vassiliki Poulia¹, Eleni Sampatakaki², Dimitrios Katsifis-Nezis³, Maria Pappa³, Evangelia Mole⁴, Sousana Gazi⁴, Elpida Skouvaklidou⁵, Nikolaos Kougkas⁵, Maria Polyzou⁶, Loukia Koutsogeorgopoulou⁶, Ioannis Xynogalas⁷, Anastasios Karamanakos⁷, Konstantinos D Vassilakis¹, Evangelos Papadimitriou⁸, Charalampos Papagoras⁸, Gerasimos Evangelatos⁹, Nafsika Gerolymatou¹⁰, Paraskevi V Voulgari¹⁰ and George E Fragoulis¹, ¹First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ²Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ³Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁴Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁵⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ⁶Department of Pathophysiology, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁷Department of Rheumatology, Evangelismos General Hospital, Athens, Attiki, Greece, ⁸First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece, ⁹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Bimekizumab, a dual IL-17 A and F blocker, has recently been added in the therapeutic rheumatologist’s armamentarium of PsA, but real-world evidence is lacking.…
Abstract Number: 1373 • ACR Convergence 2025
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Osteoporosis is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF)…
Abstract Number: 1372 • ACR Convergence 2025
Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors are recommended for patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic or biologic disease-modifying antirheumatic…
Abstract Number: 1366 • ACR Convergence 2025
Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
Rémi Marty¹, Baran Ufuktepe², Nicola Tilt³, Flore Decuypere⁴, Angela Blake³, Sandeep Kiri³ and Mohammed Soomro³, ¹UCB Pharma, Brussels, Belgium, Anderlecht, Belgium, ²UCB Pharma Istanbul, Turkey, istanbul, Turkey, ³UCB Pharma, Slough, United Kingdom, Slough, United Kingdom, ⁴UCB Pharma Brussels, Belgium, Brussels, Belgium
Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA), the presence of rheumatoid factor (RF), particularly at high levels, is…
Abstract Number: 1357 • ACR Convergence 2025
Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores
Jue Hou¹, Feiqing Huang², Gregory McDermott³, Jun Wen⁴, Mary Jeffway³, Ying Qi⁵, Yunqing Han³, Tianrun Cai⁶, Florence Bourgeois⁴, Katherine Liao⁷ and Tianxi Cai², ¹University of Minnesota, Minneapolis, MN, ²Harvard T.H. Chan School of Public Health, Boston, ³Brigham and Women's Hospital, Boston, ⁴Harvard Medical School, Boston, ⁵Brigham and Women’s Hospital, Boston, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: Validated rheumatoid arthritis (RA) disease activity measures such as the Disease Activity Score-28 (DAS28) are used in clinical trials but not universally recorded in…
Abstract Number: 1129 • ACR Convergence 2025
Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
Jose Doménech Serrano¹, Ivana García Loiseau², Cristina RodrÍguez-Alvear³, Pablo Riesgo Sanchis¹, Oscar Moreno Pérez¹ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Virgen de la Peña General Hospital, Fuerteventura, Spain
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2I) proved substantial benefits in diabetes mellitus (DM), heart failure (HF) and kidney disease (KD). In pivotal trials, SGLT2Is…
Abstract Number: 1116 • ACR Convergence 2025
Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Sarah Sun¹, Cathryn Lee² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) used for cancer therapy can have varied toxicities among which pneumonitis (ICI-pneumonitis) is a rare (< 5%) but often fatal…
Abstract Number: 2698 • ACR Convergence 2025
Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
Yun Kyu Kim¹, Hajeong Lee², Jun Won Park³, Eun Bong Lee³, You-Jung Ha⁴ and Jin Kyun Park², ¹Seoul National University, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, South Korea, ⁴Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: The efficacy of calcineurin inhibitors in the induction treatment of lupus nephritis (LN) has been increasingly supported by recent studies. Based on these findings,…
Abstract Number: 1080 • ACR Convergence 2025
Are Minority Populations Truly Vaccine Hesitant? A Provider-Based Approach to RSV Vaccine Uptake Suggests Otherwise.
pavana sakhamuri¹, Stephen Lindsey², Cathryn Leggio³ and Ellen Mire⁴, ¹LSUHSC, Dept of Rheumatology, Lafayette, LA, ²LSUHSC, Dept of Rheumatology, NEW ORLEANS, LA, ³University Medical center, NEW ORLEANS, LA, ⁴LSUHSC, Dept of Medicine, NEW ORLEANS, LA
Background/Purpose: Respiratory Syncytial Virus (RSV) is a leading cause of hospitalization and mortality in older adults and young children, particularly those with chronic illnesses or…
Abstract Number: 2659 • ACR Convergence 2025
Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation
Jamie Chieh Lo¹, Karen H. Costenbader² and Kevin Sheng-Kai Ma³, ¹National Taiwan University Hospital, Keelung, Taipei, Taiwan (Republic of China), ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA
Background/Purpose: Treatment with dipeptidyl peptidase-4 inhibitors (DPP4i) have been shown to reduce the risk of systemic autoimmune rheumatic diseases (SARD) in patients with type 2…
Abstract Number: 0804 • ACR Convergence 2025
Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus
Grace Haeun Lee¹, Sara Barmettler², Lingxiao Zhang³ and April Jorge², ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Boston
Background/Purpose: Belimumab is a monoclonal antibody targeting B-lymphocyte stimulator (BLyS) used in the treatment of active systemic lupus erythematosus (SLE). Our objective was to investigate…
Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Francesco Fulvio Bizzarri¹, Luis Alberto Menchén Viso², Esther Chamorro De Vega³, Ofelia Baniandrés Rodríguez⁴ and Juan Carlos Nieto², ¹Hospital Universitario Clinico San Cecilio, Granada, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…
Abstract Number: 0740 • ACR Convergence 2025
Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Carmen Secada-Gómez¹, Javier Loricera², Adrian Martin-Gutierrez³, Santos Castañeda⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Aortitis associated to Giant cell arteritis (GCA) (GCA-aortitis) is one of the most severe manifestation of GCA. Tocilizumab (TCZ) has demonstrated efficacy in large-vessel…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].